Vanguard Group Inc Pharma Cyte Biotech, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 194,447 shares of PMCB stock, worth $163,335. This represents 0.0% of its overall portfolio holdings.
Number of Shares
194,447
Previous 194,518
0.04%
Holding current value
$163,335
Previous $243,000
13.17%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding PMCB
# of Institutions
29Shares Held
682KCall Options Held
0Put Options Held
0-
Geode Capital Management, LLC Boston, MA127KShares$106,3460.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$77,3537.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$69,4900.09% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny49.8KShares$41,8320.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA27.6KShares$23,1890.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $17.4M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...